Manufacturers announce positive results from phase 3 study evaluating once-daily relugolix combination therapy in women with endometriosis and priority review from FDA for use in prostate cancer (PC)

In SPIRIT 1 study, relugolix,an oral gonadotropin-releasing hormone receptor antagonist, plus estradiol & norethindrone led to reductions in pain in 74.5% of women with dysmenorrhoea vs 26.9% for placebo New Drug Application in advanced PC was accepted by FDA for priority review


Biospace Inc.